Ultragenyx Pharmaceutical reported $-91.34M in EBITDA for its fiscal quarter ending in June of 2025.





Ebitda Change Date
Acadia Pharmaceuticals USD 35.76M 447K Sep/2025
Agios Pharmaceuticals USD -125.8M 20.45M Jun/2025
Alnylam Pharmaceuticals USD 381.78M 362.95M Sep/2025
BioMarin Pharmaceutical USD 295.45M 49.49M Jun/2025
Insmed USD -297.13M 71.11M Jun/2025
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
Kyowa Hakko Kirin JPY 32.28B 13.25B Sep/2025
MacroGenics USD 21.95M 55.39M Sep/2025
Moderna USD -208M 552M Sep/2025
Neurocrine Biosciences USD 246.7M 93.8M Sep/2025
PTC Therapeutics USD -33.11M 1B Jun/2025
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Sarepta Therapeutics USD 126.42M 416.82M Jun/2025
Ultragenyx Pharmaceutical USD -91.34M 35.09M Jun/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025